Where Will Fluor Stock Be in 1 Year?

Fluor has largely stabilized after pandemic-era execution problems, with more than 80% of backlog now in reimbursable contracts and management expecting that mix to keep improving. Analysts see adjusted EPS rising 18% in 2026 and 28% in 2027, while the recent sale of its remaining NuScale stake generated an estimated $1.86 billion raw profit. The stock is up about 4% over the past 12 months and is described as reasonably valued, implying modest upside rather than a major catalyst.

Analysis

The market is likely underappreciating how much the earnings quality has changed versus the headline growth rate. A higher share of reimbursable work should compress downside volatility in margins and cash conversion, which matters more than point forecasts because it lowers the probability of another execution-driven de-rating. In other words, FLR is moving from a “can it deliver?” story to a “how much operating leverage can it show?” story, and that transition tends to support multiple expansion even before growth inflects.

The cleaner second-order winner may be the broader engineering/procurement ecosystem: suppliers tied to power, industrial, and data-center buildouts should see steadier order visibility if FLR’s backlog mix continues to shift away from lump-sum risk. On the flip side, competitors still leaning on fixed-price megaprojects may look cheap on near-term earnings but remain more exposed to cost inflation and schedule slippage, which could create relative share gains for FLR over the next 2-4 quarters.

The NuScale monetization is more important as a portfolio simplification event than as a one-time gain. Removing a volatile equity stake reduces headline noise and may make FLR screen better for quality- and cash-flow-oriented capital, but it also removes an embedded call option on SMR sentiment; that caps upside if investors were implicitly paying for that optionality. The key risk is that the market extrapolates the improved mix too quickly while execution discipline has only recently stabilized, so any single-project miss could still force a rapid reset.

Consensus appears to be treating FLR as a respectable industrial compounder rather than a repaired special situation. That may be too cautious if the mix shift is durable, because the earnings power could rerate faster than sell-side models, which are still likely anchored to normalized margins that lag the actual contract mix change by several quarters. The setup is constructive over 6-12 months, but the path likely remains choppy until the next couple of quarters confirm that better quality revenue is translating into cleaner free cash flow.

Key Decisions for Investors

• Long FLR on any post-earnings or market-wide industrial pullback; target a 6-12 month hold with upside driven by multiple rerating rather than heroic growth assumptions. Risk/reward improves if the stock stays near ~21x forward earnings while execution remains clean.
• Use FLR call spreads rather than outright equity if positioning for a 3-6 month catalyst window; the thesis is de-risking plus mix improvement, so defined-risk upside exposure is preferable to avoid a drawdown from a single project miss.
• Pair trade: long FLR / short a fixed-price-heavy E&C peer with weaker backlog quality over 6-9 months. The relative thesis is better earnings durability and lower execution risk, not just better headline growth.
• Avoid chasing SMR based on the NuScale sale headline; the cash realization is a balance-sheet/portfolio simplifier for FLR, not evidence that nuclear equity optionality should be repriced upward immediately. Wait for actual capital deployment before expressing a bullish SMR view.
• If FLR rallies sharply into the implied 28% upside area without a confirming quarter of margin/cash-flow follow-through, trim to respect the remaining execution risk; this is still a transition story, not a fully de-risked quality franchise.